Executive Summary
According to Azoth Analytics research report, the global Idiopathic Pulmonary Fibrosis Market is projected to display robust growth valued at USD 3271.3 Million in the year 2020 with North America leading the regional market share.
The primary driver of growth in the IPF market in recent years has been an increased use of the high-priced Pirfenidone (Esbriet) and Nintedanib (Ofev) brands in favour of off-label pharmacological therapies and non-pharmacological treatments. Prior to the approval of these drugs, cheap corticosteroids and immunosuppressant's were used to treat IPF despite negative recommendations in evidence-based guidelines for general treatment.
The major factors that drive the growth of the global idiopathic pulmonary fibrosis market include a rise in the prevalence of fibrotic disease and an increase in the geriatric population. In addition, a surge in demand for cost-effective drugs and the introduction of advanced treatment options propel market growth. Furthermore, changing lifestyle patterns and increasing consumption of nicotine products is providing a thrust to the market growth. Moreover, smoking tobacco and cigarettes are considered the most common cause for the development of IPF. In line with this, increasing health consciousness among the masses regarding the effective management strategies of IPF is also favouring the growth of the market.
Additionally, the advent of novel medicines and advancements in the IPF diagnostic and treatment methods, are acting as other growth-inducing factors. This, along with extensive research and development (R&D) activities and improvements in the healthcare infrastructure, represents some of the other factors anticipated to drive the market.
Moreover, to pharmacological treatments, various non-pharmacological treatments are also used for IPF patients. The most used non-pharmacological treatments are lung transplantations, mechanical ventilation, oxygen therapy, and pulmonary rehabilitation. In general, the treatment approach in IPF is largely dependent on a patient's symptoms, the stage of the disease, and a patient's overall health.
Scope of the Report
• The report presents the analysis of the Idiopathic Pulmonary Fibrosis market for the historical period of 2016-2020 and the forecast period of 2021-2026.
• The report analyses the Idiopathic Pulmonary Fibrosis Market by Value (USD Million).
• The report analyses the Idiopathic Pulmonary Fibrosis Market by Drug Type (Nintedanib, Pirfenidone, Others).
• The report analyses the Idiopathic Pulmonary Fibrosis Market by End User (Hospital & Clinics, Academic and Research Organizations, Others).
• The Global Idiopathic Pulmonary Fibrosis Market has been analysed By Region (North America, Europe, Asia Pacific).
• The Global Idiopathic Pulmonary Fibrosis Market has been analysed By Country (United States, Canada, Germany, France, United Kingdom, Spain, Italy, China, Japan, India).
• The attractiveness of the market has been presented by region, by Drug Class and by End User.
• Also, the major opportunities, trends, drivers and challenges of the industry have been analysed in the report.
• The report tracks competitive developments, strategies, mergers and acquisitions and new product development.
• The companies analysed in the report include AbbVie Inc., Bristol-Myers Squibb, F. Hoffman-La Roche, Ltd., Boehringer Ingelheim, Merck KGaA, Gilead Sciences, Liminal Biosciences, Cipla, Galapagos NV, FibroGen, Medicinova Inc.
Key Target Audience
• Pharmaceutical and Healthcare Companies
• Consulting and Advisory Firms
• Government and Policy Makers
• Regulatory Authorities
1. Report Scope and Methodology
1.1 Scope of the Report
1.2 Research Methodology
1.3 Executive Summary
2. Strategic Recommendations
3. Idiopathic Pulmonary Fibrosis Market: Product Outlook
4. Global Idiopathic Pulmonary Fibrosis Market: Sizing and Forecast
4.1 Global Idiopathic Pulmonary Fibrosis Market Size, By Value, 2016-2026
4.2 Impact of COVID-19 on Global Idiopathic Pulmonary Fibrosis Market
5. Global Idiopathic Pulmonary Fibrosis Market Segmentation - By Drug Type, By End User
5.1 Competitive Scenario of Global Idiopathic Pulmonary Fibrosis Market: By Drug Type
5.1.1 Nintedanib - Market Size and Forecast (2016-2026)
5.1.2 Pirfenidone - Market Size and Forecast (2016-2026)
5.1.3 Others - Market Size and Forecast (2016-2026)
5.2 Competitive Scenario of Global Idiopathic Pulmonary Fibrosis Market: By End User
5.2.1 Hospitals and Clinics - Market Size and Forecast (2016-2026)
5.2.2 Academics and Research Organization - Market Size and Forecast (2016-2026)
5.2.3 Others - Market Size and Forecast (2016-2026)
6. Global Idiopathic Pulmonary Fibrosis Market: Regional Analysis
6.1 Competitive Scenario of Global Idiopathic Pulmonary Fibrosis Market: By Region
7. North America Idiopathic Pulmonary Fibrosis Market: An Analysis (2016-2026)
7.1 North America Idiopathic Pulmonary Fibrosis Market: Size and Forecast (2016-2026), By Value
7.2 North America Idiopathic Pulmonary Fibrosis Market - Prominent Companies
7.3 Market Segmentation By Drug Type (Nintedanib, Pirfenidone and Others)
7.4 Market Segmentation By End User (Hospitals and Clinics, Academics and Research Organization and Others)
7.5 North America Idiopathic Pulmonary Fibrosis Market: Country Analysis
7.6 Market Opportunity Chart of North America Idiopathic Pulmonary Fibrosis Market - By Country, By Value, 2026
7.7 Competitive Scenario of North America Idiopathic Pulmonary Fibrosis Market: By Country
7.8 United States Idiopathic Pulmonary Fibrosis Market: Size and Forecast (2016-2026), By Value
7.9 United States Idiopathic Pulmonary Fibrosis Market Segmentation - By Drug Type, By End User (2016-2026)
7.10 Canada Idiopathic Pulmonary Fibrosis Market: Size and Forecast (2016-2026), By Value
7.11 Canada Idiopathic Pulmonary Fibrosis Market Segmentation - By Drug Type, By End User (2016-2026)
8. Europe Idiopathic Pulmonary Fibrosis Market: An Analysis (2016-2026)
8.1 Europe Idiopathic Pulmonary Fibrosis Market: Size and Forecast (2016-2026), By Value
8.2 Europe Idiopathic Pulmonary Fibrosis Market - Prominent Companies
8.3 Market Segmentation By Drug Type (Nintedanib, Pirfenidone, Others)
8.4 Market Segmentation By End User (Hospitals and Clinics, Academics and Research Organization, Others)
8.5 Europe Idiopathic Pulmonary Fibrosis Market: Country Analysis
8.6 Market Opportunity Chart of Europe Idiopathic Pulmonary Fibrosis Market - By Country, By Value, 2026
8.7 Competitive Scenario of Europe Idiopathic Pulmonary Fibrosis Market: By Country
8.8 Germany Idiopathic Pulmonary Fibrosis Market: Size and Forecast (2016-2026), By Value
8.9 Germany Idiopathic Pulmonary Fibrosis Market Segmentation - By Drug Type, By End User (2016-2026)
8.10 United Kingdom Idiopathic Pulmonary Fibrosis Market: Size and Forecast (2016-2026), By Value
8.11 United Kingdom Idiopathic Pulmonary Fibrosis Market Segmentation - By Drug Type, By End User (2016-2026)
8.12 France Idiopathic Pulmonary Fibrosis Market: Size and Forecast (2016-2026), By Value
8.13 France Idiopathic Pulmonary Fibrosis Market Segmentation - By Drug Type, By End User (2016-2026)
8.14 Italy Idiopathic Pulmonary Fibrosis Market: Size and Forecast (2016-2026), By Value
8.15 Italy Idiopathic Pulmonary Fibrosis Market Segmentation - By Drug Type, By End User (2016-2026)
8.16 Spain Idiopathic Pulmonary Fibrosis Market: Size and Forecast (2016-2026), By Value
8.17 Spain Idiopathic Pulmonary Fibrosis Market Segmentation - By Drug Type, By End User (2016-2026)
9. Asia Pacific Idiopathic Pulmonary Fibrosis Market: An Analysis (2016-2026)
9.1 Asia Pacific Idiopathic Pulmonary Fibrosis Market: Size and Forecast (2016-2026), By Value
9.2 Asia Pacific Idiopathic Pulmonary Fibrosis Market - Prominent Companies
9.3 Market Segmentation By Drug Type (Nintedanib, Pirfenidone, Others)
9.4 Market Segmentation By End User (Hospitals and Clinics, Academics and Research Organization, Others)
9.5 Asia Pacific Idiopathic Pulmonary Fibrosis Market: Country Analysis
9.6 Market Opportunity Chart of Asia Pacific Idiopathic Pulmonary Fibrosis Market - By Country, By Value, 2026
9.7 Competitive Scenario of Asia Pacific Idiopathic Pulmonary Fibrosis Market: By Country
9.8 China Idiopathic Pulmonary Fibrosis Market: Size and Forecast (2016-2026), By Value
9.9 China Idiopathic Pulmonary Fibrosis Market Segmentation - By Drug Type, By End User (2016-2026)
9.10 Japan Idiopathic Pulmonary Fibrosis Market: Size and Forecast (2016-2026), By Value
9.11 Japan Idiopathic Pulmonary Fibrosis Market Segmentation - By Drug Type, By End User (2016-2026)
9.12 India Idiopathic Pulmonary Fibrosis Market: Size and Forecast (2016-2026), By Value
9.13 India Idiopathic Pulmonary Fibrosis Market Segmentation - By Drug Type, By End User (2016-2026)
10. Global Idiopathic Pulmonary Fibrosis Market Dynamics
10.1 Drivers
10.2 Restraints
10.3 Trends
11. Market Attractiveness
11.1 Market Attractiveness Chart of Global Idiopathic Pulmonary Fibrosis Market - By Drug Type, 2026
11.2 Market Attractiveness Chart of Global Idiopathic Pulmonary Fibrosis Market - By End User, 2026
11.3 Market Attractiveness Chart of Global Idiopathic Pulmonary Fibrosis Market - By Region, 2026
12. Competitive Landscape
12.1 Product Pipeline of Leading Idiopathic Pulmonary Fibrosis Companies
12.2 Market Share Analysis
13. Company Analysis
13.1 AbbVie Inc.
13.2 Bristol-Myers Squibb
13.3 F. Hoffman-La Roche Ltd.
13.4 Boehringer Ingelheim
13.5 Merck KGaA
13.6 Gilead Sciences
13.7 Liminal Biosciences
13.8 Cipla
13.9 Galapagos NV
13.10 FibroGen
13.11 Medicinova Inc.
Request Sample 
Request Discount 
Inquire Before Buy
